英国发起2600万英的帕金森病试验,试验用于减缓疾病进展的药物. UK launches £26M Parkinson’s trial testing repurposed drugs to slow disease progression.

英国最大的帕金森试验 — — EJS ACT-PD — — 已经以2,600万英镑的资金启动,测试血压药物等再用途药物,并进行前列腺治疗以减缓疾病发展。 The UK’s largest Parkinson’s trial, EJS ACT-PD, has launched with £26 million in funding, testing repurposed drugs like a blood pressure medication and prostate treatment to slow disease progression. 由UCL和Newcastle大学牵头,它使用灵活设计,即时评价多种疗法,有可能切断药物开发的年份。 Led by UCL and Newcastle University, it uses a flexible design to evaluate multiple therapies at once, potentially cutting years off drug development. 审判在40多个医院招募了多达1 600名参与者,目的是改善获得治疗的机会和包容性,同时利用实时数据调整治疗方法。 Recruiting up to 1,600 participants across 40+ hospitals, the trial aims to improve access and inclusivity while using real-time data to adapt treatments. 它专注于疾病缓解疗法，而不仅仅是缓解症状，为数百万受帕金森氏症影响的人带来希望。 It focuses on disease-modifying therapies, not just symptom relief, offering hope for millions affected by Parkinson’s.